|
22
|
142
|
8uudL |
Bcx2627 complexed with human fviia and soluble tissue factor. |
|
55
|
254
|
8uudH |
Bcx2627 complexed with human fviia and soluble tissue factor. |
|
57
|
254
|
8qodB |
Crystal structure of fviia in complex with a benzamidine-based inhibitor |
|
29
|
141
|
8qodA |
Crystal structure of fviia in complex with a benzamidine-based inhibitor |
|
58
|
254
|
8qq6B |
Crystal structure of fviia in complex with a benzamidine-based inhibitor |
|
28
|
141
|
8qq6A |
Crystal structure of fviia in complex with a benzamidine-based inhibitor |
|
21
|
142
|
9p0xV |
Nanodisc-embedded human tf/fviia/xk1 in complex with 10h10 fab (nanodisc-subtracted) |
|
43
|
254
|
9p0xS |
Nanodisc-embedded human tf/fviia/xk1 in complex with 10h10 fab (nanodisc-subtracted) |
|
41
|
254
|
8cn9C |
Factor vii binding fab of the bispecific antibody hmb-001 in complex with factor vii |
|
13
|
94
|
8cn9D |
Factor vii binding fab of the bispecific antibody hmb-001 in complex with factor vii |
|
3
|
46
|
1f7eA |
The first egf-like domain from human blood coagulation fvii, nmr, 20 structures |
|
4
|
46
|
1ff7A |
The first egf-like domain from human blood coagulation fvii (fucosylated at ser-60), nmr, 20 structures |
|
6
|
41
|
1bf9A |
N-terminal egf-like domain from human factor vii, nmr, 23 structures |
|
60
|
254
|
5l30H |
Factor viia in complex with the inhibitor (2r,15r)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-7-[1-(1h-tetrazol-5-yl)cyclopropyl]-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione |
|
8
|
37
|
5ky3B |
Mouse pofut1 in complex with mouse factor vii egf1 mutant (t101a) and gdp-fucose |
|
12
|
55
|
5l2yL |
Factor viia in complex with the inhibitor 1-[(2r,15r)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,20-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6,8,10(21),16,19-hexaen-7-yl] cyclobutane-1-carboxylic acid |
|
59
|
254
|
5l2zH |
Factor viia in complex with the inhibitor 1-[(2r,15r)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaen-7-yl]cyclohexane-1-carboxylic acid |
|
9
|
39
|
5l0sB |
Human poglut1 in complex with factor vii egf1 and udp |
|
59
|
254
|
5l2yH |
Factor viia in complex with the inhibitor 1-[(2r,15r)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,20-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6,8,10(21),16,19-hexaen-7-yl] cyclobutane-1-carboxylic acid |
|
10
|
40
|
5ky2B |
Mouse pofut1 in complex with o-glucosylated mouse factor vii egf1 and gdp |
|
13
|
56
|
5l30L |
Factor viia in complex with the inhibitor (2r,15r)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-7-[1-(1h-tetrazol-5-yl)cyclopropyl]-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione |
|
8
|
38
|
5kxhB |
Mouse pofut1 in complex with mouse factor vii egf1 and gdp |
|
13
|
58
|
5l2zL |
Factor viia in complex with the inhibitor 1-[(2r,15r)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaen-7-yl]cyclohexane-1-carboxylic acid |
|
60
|
254
|
5i46H |
Factor viia in complex with the inhibitor (2r,15r)-2-[(1-aminoisoquinolin-6-yl)amino]-8-fluoro-7-hydroxy-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione |
|
29
|
144
|
4zmaL |
Crystal structure of a fviia-trypsin chimera (st) in complex with soluble tissue factor |
|
60
|
249
|
4zmaH |
Crystal structure of a fviia-trypsin chimera (st) in complex with soluble tissue factor |
|
12
|
57
|
4yt7L |
Factor viia in complex with the inhibitor 2-(2-{(r)-[(4-carbamimidoylphenyl)amino][5-ethoxy-2-fluoro-3-(propan-2-yloxy)phenyl]methyl}-1h-imidazol-4-yl)benzamide |
|
19
|
96
|
4z6aL |
Crystal structure of a fviia-trypsin chimera (yt) in complex with soluble tissue factor |
|
63
|
249
|
4z6aH |
Crystal structure of a fviia-trypsin chimera (yt) in complex with soluble tissue factor |
|
61
|
254
|
4yt7H |
Factor viia in complex with the inhibitor 2-(2-{(r)-[(4-carbamimidoylphenyl)amino][5-ethoxy-2-fluoro-3-(propan-2-yloxy)phenyl]methyl}-1h-imidazol-4-yl)benzamide |
|
53
|
254
|
3th3H |
Mg2+ is required for optimal folding of the gamma-carboxyglutamic acid (gla) domains of vitamin k-dependent clotting factors at physiological ca2+ |
|
56
|
254
|
3th2H |
Mg2+ is required for optimal folding of the gamma-carboxyglutamic acid (gla) domains of vitamin k-dependent clotting factors at physiological ca2+ |
|
27
|
142
|
3th2L |
Mg2+ is required for optimal folding of the gamma-carboxyglutamic acid (gla) domains of vitamin k-dependent clotting factors at physiological ca2+ |
|
17
|
96
|
3th3L |
Mg2+ is required for optimal folding of the gamma-carboxyglutamic acid (gla) domains of vitamin k-dependent clotting factors at physiological ca2+ |
|
54
|
254
|
3th4H |
Mg2+ is required for optimal folding of the gamma-carboxyglutamic acid (gla) domains of vitamin k-dependent clotting factors at physiological ca2+ |
|
28
|
142
|
3th4L |
Mg2+ is required for optimal folding of the gamma-carboxyglutamic acid (gla) domains of vitamin k-dependent clotting factors at physiological ca2+ |
|
12
|
55
|
5u6jL |
Factor viia in complex with the inhibitor 3-{[(2r)-17-ethyl-4-methyl-3,12-dioxo-7-[(propan-2-yl)sulfonyl]-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaen-2-yl]amino}benzamide |
|
61
|
254
|
5u6jH |
Factor viia in complex with the inhibitor 3-{[(2r)-17-ethyl-4-methyl-3,12-dioxo-7-[(propan-2-yl)sulfonyl]-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaen-2-yl]amino}benzamide |
|
12
|
55
|
5tqeL |
Factor viia in complex with the inhibitor (5r)-5-[(1-aminoisoquinolin-6-yl)amino]-19-(cyclopropylsulfonyl)-3-methyl-13-oxa-3,15-diazatricyclo[14.3.1.1~6,10~]henicosa-1(20),6(21),7,9,16,18-hexaene-4,14-dione |
|
59
|
254
|
5tqeH |
Factor viia in complex with the inhibitor (5r)-5-[(1-aminoisoquinolin-6-yl)amino]-19-(cyclopropylsulfonyl)-3-methyl-13-oxa-3,15-diazatricyclo[14.3.1.1~6,10~]henicosa-1(20),6(21),7,9,16,18-hexaene-4,14-dione |
|
59
|
254
|
5tqgH |
Factor viia in complex with the inhibitor (5r,11r)-11-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-16-(cyclopropylsulfonyl)-7-(2,2-difluoroethoxy)-5,13-dimethyl-2,13-diazatricyclo[13.3.1.1~6,10~]icosa-1(19),6(20),7,9,15,17-hexaene-3,12-dione |
|
12
|
55
|
5tqfL |
Factor viia in complex with the inhibitor (11r)-11-[(1-aminoisoquinolin-6-yl)amino]-16-(cyclopropylsulfonyl)-13-methyl-2,13-diazatricyclo[13.3.1.1~6,10~]icosa-1(19),6(20),7,9,15,17-hexaene-3,12-dione |
|
59
|
254
|
5tqfH |
Factor viia in complex with the inhibitor (11r)-11-[(1-aminoisoquinolin-6-yl)amino]-16-(cyclopropylsulfonyl)-13-methyl-2,13-diazatricyclo[13.3.1.1~6,10~]icosa-1(19),6(20),7,9,15,17-hexaene-3,12-dione |
|
11
|
55
|
5tqgL |
Factor viia in complex with the inhibitor (5r,11r)-11-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-16-(cyclopropylsulfonyl)-7-(2,2-difluoroethoxy)-5,13-dimethyl-2,13-diazatricyclo[13.3.1.1~6,10~]icosa-1(19),6(20),7,9,15,17-hexaene-3,12-dione |
|
13
|
58
|
5patA |
Crystal structure of factor viia in complex with n-(2-amino-1h-benzimidazol-5-yl)-2-(3-chlorophenyl)acetamide |
|
12
|
56
|
5pajA |
Crystal structure of factor viia in complex with 1-(1-aminoisoquinolin-6-yl)-3-benzylurea |
|
62
|
254
|
5pb6C |
Crystal structure of factor viia in complex with n-[[3-[5-hydroxy-4-(1h-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]pentanamide |
|
63
|
254
|
5patB |
Crystal structure of factor viia in complex with n-(2-amino-1h-benzimidazol-5-yl)-2-(3-chlorophenyl)acetamide |
|
65
|
254
|
5pamB |
Crystal structure of factor viia in complex with 2-[(1-aminoisoquinolin-6-yl)amino]-2-(5-ethoxy-2-fluorophenyl)-1-(2-phenylpyrrolidin-1-yl)ethanone |
|
12
|
58
|
5parA |
Crystal structure of factor viia in complex with 1h-benzimidazol-2-amine |
